Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration

Geoffrey G. Emerson, Christina Flaxel, Andreas (Andy) Lauer, J. Timothy Stout, M. Vaughn Emerson, Susan Nolte, David Wilson, Michael Klein

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age-related macular degeneration (AMD). METHODS: For this prospective, nonrandomized, observational case series, 41 eyes from 41 patients with neovascular AMD received intravitreous pegaptanib (1 mg) injections repeated every 6 weeks. The primary outcome measure was central foveal thickness measured by OCT. Secondary outcomes were fluorescein angiographic leakage and visual acuity. RESULTS: Mean thickness of the central area on OCT decreased from 340 ± 24 μm to 299 ± 14 μm after 12 weeks of pegaptanib injections. This represents a reduction in thickening of 32%. Fluorescein angiograms with definite leakage decreased from 100% to 81%, and mean visual acuity decreased from 20/116 to 20/120. CONCLUSIONS: Intravitreal injections of pegaptanib at 6-week intervals result in a moderate reduction of central foveal thickness in eyes with subfoveal neovascular AMD. This presents a modest effect relative to that reported with other anti-angiogenic agents.

Original languageEnglish (US)
Pages (from-to)724-729
Number of pages6
JournalRetina
Volume27
Issue number6
DOIs
StatePublished - Jul 2007

Fingerprint

Optical Coherence Tomography
Macular Degeneration
Fluorescein
Visual Acuity
Intravitreal Injections
Injections
Therapeutics
Angiography
Outcome Assessment (Health Care)
pegaptanib

Keywords

  • Age-related macular degeneration
  • Choroidal neovascularization
  • Macugen
  • Optical coherence tomography
  • Pegaptanib
  • Retinal edema

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration. / Emerson, Geoffrey G.; Flaxel, Christina; Lauer, Andreas (Andy); Stout, J. Timothy; Emerson, M. Vaughn; Nolte, Susan; Wilson, David; Klein, Michael.

In: Retina, Vol. 27, No. 6, 07.2007, p. 724-729.

Research output: Contribution to journalArticle

@article{445d08a3e4a94b90a3d203979c62d15b,
title = "Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration",
abstract = "BACKGROUND: To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age-related macular degeneration (AMD). METHODS: For this prospective, nonrandomized, observational case series, 41 eyes from 41 patients with neovascular AMD received intravitreous pegaptanib (1 mg) injections repeated every 6 weeks. The primary outcome measure was central foveal thickness measured by OCT. Secondary outcomes were fluorescein angiographic leakage and visual acuity. RESULTS: Mean thickness of the central area on OCT decreased from 340 ± 24 μm to 299 ± 14 μm after 12 weeks of pegaptanib injections. This represents a reduction in thickening of 32{\%}. Fluorescein angiograms with definite leakage decreased from 100{\%} to 81{\%}, and mean visual acuity decreased from 20/116 to 20/120. CONCLUSIONS: Intravitreal injections of pegaptanib at 6-week intervals result in a moderate reduction of central foveal thickness in eyes with subfoveal neovascular AMD. This presents a modest effect relative to that reported with other anti-angiogenic agents.",
keywords = "Age-related macular degeneration, Choroidal neovascularization, Macugen, Optical coherence tomography, Pegaptanib, Retinal edema",
author = "Emerson, {Geoffrey G.} and Christina Flaxel and Lauer, {Andreas (Andy)} and Stout, {J. Timothy} and Emerson, {M. Vaughn} and Susan Nolte and David Wilson and Michael Klein",
year = "2007",
month = "7",
doi = "10.1097/IAE.0b013e318042b3c8",
language = "English (US)",
volume = "27",
pages = "724--729",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration

AU - Emerson, Geoffrey G.

AU - Flaxel, Christina

AU - Lauer, Andreas (Andy)

AU - Stout, J. Timothy

AU - Emerson, M. Vaughn

AU - Nolte, Susan

AU - Wilson, David

AU - Klein, Michael

PY - 2007/7

Y1 - 2007/7

N2 - BACKGROUND: To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age-related macular degeneration (AMD). METHODS: For this prospective, nonrandomized, observational case series, 41 eyes from 41 patients with neovascular AMD received intravitreous pegaptanib (1 mg) injections repeated every 6 weeks. The primary outcome measure was central foveal thickness measured by OCT. Secondary outcomes were fluorescein angiographic leakage and visual acuity. RESULTS: Mean thickness of the central area on OCT decreased from 340 ± 24 μm to 299 ± 14 μm after 12 weeks of pegaptanib injections. This represents a reduction in thickening of 32%. Fluorescein angiograms with definite leakage decreased from 100% to 81%, and mean visual acuity decreased from 20/116 to 20/120. CONCLUSIONS: Intravitreal injections of pegaptanib at 6-week intervals result in a moderate reduction of central foveal thickness in eyes with subfoveal neovascular AMD. This presents a modest effect relative to that reported with other anti-angiogenic agents.

AB - BACKGROUND: To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age-related macular degeneration (AMD). METHODS: For this prospective, nonrandomized, observational case series, 41 eyes from 41 patients with neovascular AMD received intravitreous pegaptanib (1 mg) injections repeated every 6 weeks. The primary outcome measure was central foveal thickness measured by OCT. Secondary outcomes were fluorescein angiographic leakage and visual acuity. RESULTS: Mean thickness of the central area on OCT decreased from 340 ± 24 μm to 299 ± 14 μm after 12 weeks of pegaptanib injections. This represents a reduction in thickening of 32%. Fluorescein angiograms with definite leakage decreased from 100% to 81%, and mean visual acuity decreased from 20/116 to 20/120. CONCLUSIONS: Intravitreal injections of pegaptanib at 6-week intervals result in a moderate reduction of central foveal thickness in eyes with subfoveal neovascular AMD. This presents a modest effect relative to that reported with other anti-angiogenic agents.

KW - Age-related macular degeneration

KW - Choroidal neovascularization

KW - Macugen

KW - Optical coherence tomography

KW - Pegaptanib

KW - Retinal edema

UR - http://www.scopus.com/inward/record.url?scp=34447318633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447318633&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e318042b3c8

DO - 10.1097/IAE.0b013e318042b3c8

M3 - Article

C2 - 17621181

AN - SCOPUS:34447318633

VL - 27

SP - 724

EP - 729

JO - Retina

JF - Retina

SN - 0275-004X

IS - 6

ER -